|Daily Range||$105.65 - $106.78|
|52-Week Range||$104.55 - $156.77|
|Dividend (Yield)||$0.00 (1.7%)|
|Average Daily Volume||133,403|
|Current FY EPS||$7.79|
News & Commentary
3 reasons this 3D bioprinting company might be in for a Happy New Year.
Shares catapulted higher last year because of increasing sales of its vision-restoring drug Eylea and a recent FDA approval.
The two companies plan to merge and then split into three separate entities. Is there any way to tell how this will shake out?
Four drugs made a huge impact on patient survival in 2015 according to clinical trials, and one of them can be bought over the counter.
Isis Pharmaceuticals has a whopping 30 drugs currently in clinical trials, but how these three fare will be key to its future.
An updated investor presentation appears to have bulls excited, and shares are soaring today as a result.
Cempra's stock sells off hard on good news. Is the stock now a bargain?
Regeneron's sales and income are soaring and new drug launches could lead to even better results in the future.
While there's much talk about further controlling the food supply and being a greedy corporation, few are considering the potential environmental benefits behind Monsanto's bid for Syngenta.
There's plenty of reasons why the seed and chemicals giant can break out of its funk.